Administration of vitaprost plus for prevention of infectious-inflammatory complications of transurethral prostatic resection in patients with prostatic adenoma


Cite item

Full Text

Abstract

The study of efficacy and safety of the drug vitaprost® plus (rectal suppositories) in its use for prevention of infectious-inflammatory complications after transurethral resection (TUR) of the prostate for adenoma included 55 male surgical patients with prostatic adenoma (PA). The patients were randomized into two groups matched by age, symptoms and clinical data. The control group consisted of 20 patients (group 1), the study group - of 35 patients (group 2). TUR of the prostate was made in both groups, but patients of group 2 were given additional prophylactic treatment - vitaprost® plus, one suppository before going to bed 2 days before surgery and for 8 days after TUR, the course lasted for 10 days. Postoperative blood and urine samples showed inflammatory changes more often in group 1, free of infection bacterial tests were more often in group 2. Renal microcirculation in group 1 after TUR evidenced for functional depression on perfusion intensity and renal ischemia and congestion. These changes persisted on postoperative day 8, being a potential cause of renal inflammation and ascending pyelonephritis. Group 2 patients exhibited insignificant postoperative microcirculatory disorders in the kidneys and were not registered on postoperative day 8. Infectious-inflammatory complications in group 1 patients were registered much more frequently than in group 2 patients. Thus, vitaprost® plus can be recommended for prophylaxis of infectious-inflammatory complications of TUR in PA patients.

References

  1. Винаров А. З., Асламазов Э. Г. В кн.: Материалы X Российского съезда урологов. Москва, 1-3 окт. 2002 года. М.: Информполиграф; 2002. 33-42.
  2. Лопаткин Н. А. (ред.). Рациональная фармакотерапия в урологии. M.; 2006.
  3. Лоран О. Б., Лукьянов И. В. Что нового в лечении ДГПЖ: взгляд эксперта. Рус. мед. журн. 2008; с. 29, т. 16.
  4. Мамаев И. Э., Шумило Д. В., Доброкачественная гиперплазия предстательной железы: клиника, диагностика, лечение. Рус. мед. журн. 2007; 15(12).
  5. Переверзев А. С., Сергиенко Н. Ф., Илюхин Ю. А. Заболевания предстательной железы. Харьков; 2005.
  6. Пушкарь Ю. Д., Раснер П. И. Сравнительная оценка эффективности и безопасности комбинированной медикаментозной терапии больных ДГП препаратами финастерид и альфузозин. В кн.: Х Российский съезд урологов: Материалы. М.; 2002. 42-45.
  7. Ткачук В. Н., Аль-Шукри С. Х., Лукьянов А. Э. Медикаментозное лечение больных доброкачественной гиперплазией предстательной железы. СПб.; 2000.
  8. Emberton M., Andriole G. L., de la Rosette J. et al. BPH. A progressive disease of the ageing male. Urology 2003; 61: 267-273.
  9. Hennenfent B. R., Feliciano A. N. Release of obstructive prostatic disease and improvement of erectile dysfunction by repetitive prostatic massage and antimicrobial therapy. Digit. Urol. J. 1998.
  10. Hudson P. В., Boake R., Trachtenberg O. et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999; 53 (4): 690-695.
  11. Мартов А. Г., Лопаткин Н. А Эффективность и перспективы современной эндоурологии. В кн.: Материалы X Российского съезда урологов. М.: 2002. 665-684.
  12. Alschibaja М., May F., Treiber U. et al. Transurethral resection for benign prostatic hyperplasia. current developments. Urologe A 2005; 44: 499-504.
  13. Minardi D., Garofalo F., Yehia M et al. Pressure-flow studies in men with benign prostatic hypertrophy before and after treatment with transurethral needle ablation. Urol. Int. 2001; 66 (2): 89-93.
  14. Лопаткин Н. А. Осложнения ТУР предстательной железы и аденомэктомии. В кн.: Лопаткин Н. А. (ред.). Доброкачественная гиперплазия предстательной железы. М.; 1997; 163-167.
  15. Boyle P., Napalkov P. Epidemiology of benign prostatic hyperplasia: Current perspectives. Eur. Urol. 1996; 29 (Suppl. 1): 7- 11.
  16. Ferretti S., Azzolini N., Barbieri A. et al. Randomized comparison of loops for transurethral resection of the prostate; preliminary results. J. Endourol. 2004; 18 (9): 897-900.
  17. Lukacs В., Grange J. C., McCarthy C. et al. Clinical uroselectivity a 3-year follow-up in general practice. BPH Group in General practice. Eur. Urol. 1998; 33 (Suppl. 2): 28-33.
  18. Souverein P., Erken I., De la Rosette I. Et Drug treatment of BPH and hospital admission for BPH - related surgery. Eur. Urol. 2003; 43: 528-534.
  19. Wendt-Nordahl G., Hacker A., Fastenmeier K. et al. New bipolar resection device for transurethral resection of the prostate: First exvivo and in-vivo evaluation. J. Endourol. 2005; 19(10): 1203- 1209.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies